UCB is a global biopharmaceutical company dedicated to improving the lives of people living with severe neurological and autoimmune conditions. With a strong commitment to science, innovation, and patient value, UCB focuses on delivering impactful solutions that help patients achieve the best possible outcomes.
The company employs approximately 9,000 people across nearly 40 countries, combining deep scientific expertise with advanced technologies and a patient centric approach that drives all aspects of its work.
